{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:41:11Z","timestamp":1793133671420,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"ImmunoGen, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ygyno.2020.01.037","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T08:54:34Z","timestamp":1582016074000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer"],"prefix":"10.1016","volume":"157","author":[{"given":"David M.","family":"O'Malley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar M.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-5472","authenticated-orcid":false,"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M.","family":"Mantia-Smaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Gonz\u00e1lez","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Bratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.01.037_bb0005","first-page":"426","article-title":"Management of newly diagnosed or recurrent ovarian cancer","volume":"16","author":"Matulonis","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0010","doi-asserted-by":"crossref","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","article-title":"Treatment of recurrent ovarian cancer","volume":"28","author":"Pignata","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0015","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0025","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: a critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0030","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0035","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0045","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2011","key":"10.1016\/j.ygyno.2020.01.037_bb0050","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1634\/theoncologist.2018-0459","article-title":"Is targeting the folate receptor in ovarian cancer coming of age?","volume":"24","author":"Birrer","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0060","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2147\/OTT.S40947","article-title":"Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review","volume":"7","author":"Marchetti","year":"2014","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0075","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0080","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: state of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1358\/dof.2016.041.09.2544475","article-title":"Mirvetuximab soravtansine. FR\u03b1-targeting ADC; treatment of epithelial ovarian cancer","volume":"41","author":"Gunderson","year":"2016","journal-title":"Drugs Future"},{"issue":"2015","key":"10.1016\/j.ygyno.2020.01.037_bb0090","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR alpha-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0095","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-10-0645","article-title":"Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability","volume":"9","author":"Oroudjev","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117523","article-title":"High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction","volume":"10","author":"Goldmacher","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","article-title":"Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models","volume":"18","author":"Ponte","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0120","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0125","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.biopha.2018.03.061","article-title":"The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: a review","volume":"102","author":"Chellappan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/IGC.0b013e31821b2669","article-title":"Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer","volume":"21","author":"Ledermann","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0140","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-14-1312","article-title":"New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances","volume":"20","author":"Liu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0145","first-page":"118","article-title":"Targeting the folate receptor for the treatment of ovarian cancer","volume":"4","author":"Lutz","year":"2015","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/biomedicines4030014","article-title":"Antibody-drug conjugates for cancer therapy","volume":"4","author":"Parslow","year":"2016","journal-title":"Biomedicines"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0155","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/fon-2017-0646","article-title":"FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0160","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0165","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0170","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0175","first-page":"212558","article-title":"Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations","volume":"7","author":"Liu","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0180","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ejca.2011.03.005","article-title":"Haematologic toxicities associated with the addition of bevacizumab in cancer patients","volume":"47","author":"Schutz","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0185","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.037_bb0190","first-page":"59","article-title":"Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives","volume":"8","author":"McClung","year":"2016","journal-title":"Int. J. Women\u2019s Health"},{"key":"10.1016\/j.ygyno.2020.01.037_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2018.10.031","article-title":"Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): a Korean Gynecologic Oncology Group study (KGOG 3041)","volume":"152","author":"Lee","year":"2019","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:51:36Z","timestamp":1758772296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820300901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0090825820300901"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.037","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}